Sommers, Katherine R.Skiles, JodiLelan, BrianRowan, Courtney M.2023-11-162023-11-162022Sommers KR, Skiles J, Leland B, Rowan CM. Posterior Reversible Encephalopathy Syndrome: Incidence and Clinical Characteristics in Children With Cancer. J Pediatr Hematol Oncol. 2022;44(2):54-59. doi:10.1097/MPH.0000000000002153https://hdl.handle.net/1805/37101The etiology and outcomes of posterior reversible encephalopathy syndrome (PRES) in children with cancer are not well understood. We aim to determine the incidence of PRES, describe associated morbidity and mortality, and better understand risk factors in this patient population. 473 children with a hematologic malignancy or post-allogeneic hematopoietic cell transplantation (HCT) between June 2015 and June 2020 were screened for PRES to determine incidence and whether age or underlying diagnosis are associated with development of PRES. We conducted a case-control study to evaluate whether comorbidities or chemotherapeutic agents are associated with PRES. Children with PRES were matched with two controls based on age and underlying diagnosis to identify additional risk factors. Fourteen patients developed PRES, with an incidence of 5.9/1000 people/year. Those diagnosed with PRES had commonly described PRES symptoms: hypertension, seizures, nausea/vomiting, altered mental status, and headaches. All patients received an MRI, and most had findings consistent with PRES. HCT was associated with the development of PRES. The use of Etoposide was associated with PRES but comorbidities, steroids and calcineurin inhibitors were not. While PRES was infrequent in this population, it is associated with high morbidity and mortality, with ICU admissions and an overall hospital mortality, due to secondary causes, of 29%.en-USPublisher PolicyPosterior reversible encephalopathy syndrome (PRES)Pediatric oncologyCase-controlRetrospective cohortArticle